Longevity medicine continues to explore how different compounds may influence cellular aging, mitochondrial function, autophagy, inflammation, and the accumulation of senescent cells. Fisetin, quercetin, NAD+ precursors, rapamycin, and dasatinib have each received attention for different mechanisms related to these processes.
Combining fisetin, quercetin, NAD+ precursors, rapamycin, and dasatinib represents an experimental approach to longevity medicine that separates cellular maintenance, autophagy, and senolytic clearance into distinct phases rather than using every agent simultaneously. Because rapamycin and dasatinib are prescription medications with significant risks, any clinical use requires strict medical oversight.
Executive Summary
Combining fisetin, quercetin, NAD+ precursors, rapamycin, and dasatinib into a single protocol represents the cutting edge of experimental longevity medicine, but these agents should not be treated as a continuous, simultaneous stack because of potential drug interactions, immunosuppression, and toxicity.
In clinical longevity research, the compounds are organized into a sequenced schedule that separates daily cellular maintenance from intermittent approaches intended to clear senescent cells.
Dasatinib is a prescription chemotherapy drug associated with substantial toxicity risks, including bone marrow suppression and pleural effusion. Rapamycin is a powerful immunosuppressant.
The framework described here is experimental and intended for clinical trials or highly monitored specialized practices.
Protocol Structure Overview
To prevent metabolic conflicts and manage patient safety, the framework separates the compounds into three distinct, non-overlapping operational phases:
- Chronic Maintenance Phase: NAD+ precursors and low-dose quercetin
- Gerostatic Autophagy Phase: Intermittent rapamycin
- Senolytic Clearance Phase: Intermittent dasatinib, quercetin, and fisetin
The central principle is separation. The source protocol specifically emphasizes that the agents are not intended to be taken together continuously and that other phases are paused during the intermittent senolytic period.
Phase 1: Chronic Maintenance
The chronic maintenance phase focuses on maintaining systemic NAD+ levels and providing baseline cellular protection without triggering the heavier biological resets associated with the later phases.
NAD+ precursors such as NMN or NR are included for mitochondrial support and DNA repair, while quercetin is used for its anti-inflammatory and mild senomorphic activity.
At lower amounts, the protocol characterizes quercetin as a daily antioxidant, anti-inflammatory, and mild senomorphic. In this context, the goal is to suppress harmful secretions associated with senescent cells rather than produce a true senolytic effect.
This distinction is important because the protocol treats maintenance quercetin and the substantially more intensive senolytic use of quercetin as separate applications.
Phase 2: Gerostatic Autophagy
The second phase introduces rapamycin as an intermittent prescription therapy intended to influence aging through mTOR regulation and autophagy.
The purpose of this phase is to promote gerostasis while encouraging intracellular cleansing through downregulation of the mTORC1 pathway.
Because rapamycin is an immunosuppressive prescription medication, this portion of the protocol requires individualized medical management.
The original framework also separates NAD+ precursor use from the rapamycin treatment window in an effort to avoid conflicting cellular signals and support the intended autophagy response.
Phase 3: Senolytic Clearance
The senolytic clearance phase is the most aggressive portion of the protocol. It is designed around intermittent exposure rather than continuous treatment and focuses on selectively encouraging senescent, or “zombie,” cells to undergo apoptosis.
The protocol combines dasatinib and quercetin (D+Q), with fisetin incorporated as an additional senolytic compound. All maintenance supplements and the rapamycin phase are paused during this treatment window.
The proposed mechanism of D+Q involves targeting anti-apoptotic pathways used by senescent cells for survival, including BCL-2, BCL-xL, and survivin.
Fisetin is incorporated with the goal of broadening the types of senescent cells targeted, including adipose and vascular senescent cells.
Because dasatinib is a potent chemotherapy medication and the combination remains experimental in longevity medicine, this phase requires particularly strict medical supervision rather than self-directed use.
Mandatory Clinical Monitoring
Implementing an advanced experimental protocol of this type requires rigorous screening and ongoing laboratory monitoring.
CBC with Differential: Used to monitor for transient neutropenia or thrombocytopenia associated with bone marrow suppression. The source protocol calls for testing around dasatinib treatment.
Metabolic and Lipid Panels: Rapamycin can produce changes in fasting glucose, HbA1c, triglycerides, and LDL cholesterol, making ongoing metabolic monitoring important.
Liver and Kidney Function: Dasatinib and high-dose flavonoids place demands on hepatic and renal clearance pathways. Relevant markers include ALT, AST, and eGFR.
Baseline testing and follow-up monitoring allow clinicians to evaluate whether treatment remains appropriate and identify potential complications before continuing therapy.
Absolute Contraindications
The original protocol identifies several circumstances in which treatment should not be initiated.
Active Infections: Rapamycin suppresses immune activity, while senescent cells can temporarily play a role in wound healing. The protocol therefore advises avoiding treatment during active infections and around surgical procedures.
Pre-existing Cytopenias: Patients with anemia, low platelet counts, or a history of fluid retention may face additional risks from dasatinib, including severe bleeding and pleural effusion.
Cardiovascular Issues: A history of pleural effusion, significant fluid retention, or substantial cardiovascular disease requires particular caution.
Extensive Drug Interactions: The protocol highlights CYP3A4-mediated interactions as an important concern, particularly when patients use other prescription medications.
Drug Interaction Alerts – CYP3A4
Dasatinib and quercetin can interact with CYP3A4 pathways, creating the potential for clinically significant changes in medication exposure.
A complete medication reconciliation is therefore required before initiating the protocol.
Medication classes specifically highlighted in the source include:
- Statins: Potentially increased risk of myopathy and rhabdomyolysis
- Blood Thinners: Potentially increased bleeding risk
- Calcium Channel Blockers: Potential hypotension risk
- Immunosuppressants: Potential additive immunosuppression
- Antifungals: Potential for increased toxicity
- Certain Antibiotics: Potential changes in drug metabolism
A comprehensive medication review should occur before any phase involving prescription medications, with alternatives or adjustments considered by the treating clinician when necessary.
Pharmacy Preparation & Dispensing Guidelines
The protocol also establishes specific considerations for pharmacy teams responsible for prescription verification, dispensing, and patient counseling.
Dasatinib: As a prescription chemotherapy agent, dasatinib requires a valid prescription from an authorized prescriber. The source emphasizes limited dispensing aligned with the prescribed intermittent treatment plan rather than continuous refills. Patients must also receive counseling regarding bleeding, infection, fluid accumulation, and pleural effusion risks.
Rapamycin: Sirolimus is also prescription-only. Counseling should address immunosuppression, delayed wound healing, and possible effects on glucose and lipid levels.
Quercetin and Fisetin: The source recommends pharmaceutical-grade, third-party-tested products and stresses the importance of distinguishing ordinary maintenance use from the much more intensive experimental senolytic application. Separate packaging may help prevent patient confusion.
Patient Instructions and Safety Considerations
Patients participating in a medically supervised experimental protocol should understand the warning signs that require immediate communication with their healthcare provider.
Treatment should be stopped and the provider contacted if a patient develops:
- Unexplained bruising or bleeding
- Shortness of breath, chest pain, or swelling in the extremities
- Signs of infection, including fever, chills, or persistent cough
- Severe nausea, vomiting, or dehydration
- Rapid heart rate or palpitations
The source also stresses that patients should follow the prescribed phase structure exactly, avoid independently combining different portions of the protocol, remain appropriately hydrated, and report adverse effects promptly.
Quick Reference: Phase Transition
The overall framework follows a deliberate sequence:
Chronic Maintenance
NAD+ support and low-dose quercetin are used as the baseline cellular-maintenance component.
Gerostatic Autophagy
Intermittent rapamycin is separated from the NAD+ maintenance component to support the intended mTOR and autophagy response.
Senolytic Clearance
Dasatinib, quercetin, and fisetin are reserved for intermittent senolytic treatment periods, during which the other phases are paused.
The defining feature of the framework is not simply which compounds are included, but how they are separated to reduce biological conflicts and manage the significant risks associated with prescription agents.
Next Steps for Providers & Pharmacy
Before prescribing, providers should obtain a comprehensive medical history, review all current medications, complete appropriate baseline laboratory testing, screen for contraindications, and establish access to ongoing clinical monitoring.
Pharmacy staff should verify prescription legitimacy, confirm that dispensing corresponds with the prescribed treatment structure, review potential drug interactions, clearly differentiate products intended for different phases, and provide patient counseling about timing, side effects, and warning signs.
Documentation should include informed consent, reviewed baseline laboratory results, medication reconciliation, contraindication screening, patient education, and an established follow-up monitoring schedule.
Important Safety Information
This longevity protocol is experimental and requires physician supervision. Dasatinib and rapamycin are prescription medications with significant toxicity profiles, and their use requires individualized clinical judgment.
The information presented here is intended for educational and informational purposes only and should not be considered medical advice, diagnosis, or treatment instructions.
Patients should always consult a qualified healthcare professional before beginning any new treatment or longevity protocol.
American Medical Wellness & American Wellness Pharmacy remain focused on safety, quality, appropriate clinical monitoring, and personalized patient care.